Acute Myeloid Leukemia (AML)

R. Coleman Lindsley, MD, PhD

Institution
Hematology and Oncology Dana-Farber Cancer Institute
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
About
Dr. Robert Coleman Lindsley, M.D., PhD. is a physician scientist at Dana-Farber Cancer Institute, specializing in research topics associated with MDS. His career has developed in conjunction with his interest in how disease evolves, and in turn, how new and existing therapies can interrupt the process of disease progression. The clinical research focus he has chosen in addressing problems with MDS has led to work in two important areas; examining how the fundamental properties of MDS change over time, and the features of MDS that cause resistance to therapy. Dr. Lindsley’s efforts include

Erica Warlick, MD

Institution
Health Tree Foundation
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Aplastic Anemia
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)

Maria Baer, MD

Institution
University of Maryland Greenebaum Comprehensive Cancer Center
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Aplastic Anemia
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
About
Maria Baer joined the University of Maryland Marlene and Stewart Greenebaum Cancer Center in Baltimore, Maryland in 2007 as director of hematologic malignancies and professor of medicine and molecular medicine, University of Maryland School of Medicine. She previously served as chief of the leukemia section at Roswell Park Cancer Institute and professor of medicine and associate professor of molecular pharmacology and cancer therapeutics at the University at Buffalo School of Medicine and Biomedical Sciences in Buffalo, New York.

Pamela Becker, MD, PhD

Institution
City of Hope
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
About
Dr. Becker is pursuing several areas of research investigation, including 1) the mechanism of adhesion mediated chemotherapy resistance in acute myeloid leukemia and 2) hematopoietic stem cell gene transfer for a genetic disorder of DNA repair, Fanconi anemia. TODO: Above paragraph was copied from online profile, may need to be edited.

Mikkael Sekeres, MD, MS

Institution
Sylvester Comprehensive Cancer Center and University of Miami
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Myelodysplastic Syndromes (MDS)
About
Mikkael A. Sekeres, MD, MS has been Medical Advisory Board Co-Chair since 2004. He is currently the Physician Liaison in Hematology and Chief of the Division of Hematology at the Sylvester Comprehensive Center at the University. Previously, Dr. Sekeres was the professor of medicine, director of the leukemia program, and Vice Chair for Clinical Research at the Cleveland Clinic Taussig Cancer Institute in Ohio. He earned his medical degree and a master’s degree in clinical epidemiology from the University of Pennsylvania School of Medicine. Dr. Sekeres completed his postgraduate training at

Richard M. Stone, MD

Institution
Dana-Farber Cancer Institute
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
About
Dr. Stone received his MD in 1981 from Harvard Medical School, his internal medicine residency training at Brigham and Women's Hospital, and his hematology-oncology fellowship at DFCI. He has performed numerous laboratory and clinical studies on acute leukemia and related disorders, and frequently participates in grand rounds worldwide. He is currently the Director of the Adult Acute Leukemia Program at DFCI, serves on the Medical Oncology Board of the American Board of Internal Medicine, and is vice chair of the Leukemia Core Committee for the national cooperative trials group Cancer and

How do I get my medical records from a doctor?

If you want a copy of your medical records, you  must submit a written request to the hospital or the doctor's office. The law requires that patients provide doctors with written authorization to disclose medical records or the information contained in them. Some hospitals have their own form that needs to be completed. Patients may receive copies of their medical records, however the originals must remain in the physician's or hospital's file.  Please consult with your physician's office for access to digital records.

How long can I stay on cyclosporine?

Cyclosporine: Cyclosporine is used along with antithymocyte globulin (ATG), another immunosuppressant, for treating aplastic anemia and some other forms of bone marrow failure. is an immunosuppressive drug that works by preventing T-lymphocytes from becoming active. Once the T-lymphocytes are turned off, they stop attacking stem cells: Cells in the body that develop into other cells. There are two main sources of stem cells. Embryonic stem cells come from human embryos and are used in medical research. Adult stem cells in the body repair and maintain the organ or tissue in which they are found. Blood-forming (hemapoietic) stem… in the bone marrow: The soft, spongy tissue inside most bones. Blood cells are formed in the bone marrow. . That means stem cells may be able to grow back. It is used along with antithymocyte globulin: ATG is an immunosuppressant, a drug that lowers the body's immune response. It is typically used with cyclosporine as the first-line immunosuppressive therapy (IS) to treat patients with acquired aplastic anemia. In some cases it is used as a treatment for patients with MDS and PNH. (ATG) as a standard treatment for aplastic anemia: (ay-PLASS-tik uh-NEE_mee-uh) A rare and serious condition in which the bone marrow fails to make enough blood cells - red blood cells, white blood cells, and platelets. The term aplastic is a Greek word meaning not to form. Anemia is a condition that happens when red blood cell count is low. Most… , and may also be used to treat MDS and PNH.

Some aplastic anemia patients may require prolonged ongoing treatment with cyclosporine to prevent or minimize the risk of disease relapse aplastic anemia coming back. Generally speaking, patients can remain on cyclosporine indefinitely, as long as there is evidence that the drug is providing some benefit and there are no unwanted or adverse side effects.

For patients who respond well to cyclosporine, alone or in combination with antithymocyte globulin (ATG), hematologists may reduce the cyclosporine dosage. Tapering, or reducing, the dosage is done slowly over a long period of time. If low blood counts and disease symptoms return, your doctor may increase or restart cyclosporine. For those who experience bad side effects such as kidney toxicity, the drug must be discontinued.

Website Feedback

Please use this feedback form to report website issues only. For other issues concerning patients and families, please email help@aamds.org or use the Patient and Family Helpline here.